383 related articles for article (PubMed ID: 26986538)
21. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
22. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
Jeruss JS; Mittendorf EA; Tucker SL; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2008 Jan; 26(2):246-52. PubMed ID: 18056680
[TBL] [Abstract][Full Text] [Related]
23. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
24. Validation of the AJCC 8th prognostic system for breast cancer in an Asian healthcare setting.
Wong RX; Wong FY; Lim J; Lian WX; Yap YS
Breast; 2018 Aug; 40():38-44. PubMed ID: 29677569
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Tarantino P; Jin Q; Tayob N; Jeselsohn RM; Schnitt SJ; Vincuilla J; Parker T; Tyekucheva S; Li T; Lin NU; Hughes ME; Weiss AC; King TA; Mittendorf EA; Curigliano G; Tolaney SM
JAMA Oncol; 2022 Aug; 8(8):1177-1183. PubMed ID: 35737367
[TBL] [Abstract][Full Text] [Related]
27. Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.
Lee KH; Kim EY; Park YL; Do SI; Chae SW; Park CH
Tumour Biol; 2017 Jun; 39(6):1010428317710575. PubMed ID: 28621227
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
30. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
Bertucci F; Finetti P; Viens P; Birnbaum D
Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
[TBL] [Abstract][Full Text] [Related]
31. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
[TBL] [Abstract][Full Text] [Related]
32. External verification and improvement of the Neo-Bioscore staging system in a Chinese cohort.
Geng R; Min N; Zheng Y; Hong C; Wu R; Wu H; Wei Y; Zhang Y; Li X
Ann Transl Med; 2022 Jun; 10(11):626. PubMed ID: 35813331
[TBL] [Abstract][Full Text] [Related]
33. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor.
Loibl S; Weber K; Huober J; Krappmann K; Marmé F; Schem C; Engels K; Pfitzner BM; Kümmel S; Furlanetto J; Hartmann A; Darb-Esfahani S; Müller V; Staebler A; von Minckwitz G; Kronenwett R; Denkert C
Clin Cancer Res; 2018 Jul; 24(14):3358-3365. PubMed ID: 29618617
[No Abstract] [Full Text] [Related]
34. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
35. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
39. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.
Chavez-MacGregor M; Mittendorf EA; Clarke CA; Lichtensztajn DY; Hunt KK; Giordano SH
Oncologist; 2017 Nov; 22(11):1292-1300. PubMed ID: 28592619
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
Peiffer DS; Zhao F; Chen N; Hahn OM; Nanda R; Olopade OI; Huo D; Howard FM
JAMA Oncol; 2023 Apr; 9(4):500-510. PubMed ID: 36821125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
